USANA Health Sciences, Inc. (NYSE:USNA) Shares Bought by Rhumbline Advisers

Rhumbline Advisers raised its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 28.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,516 shares of the company’s stock after buying an additional 8,710 shares during the period. Rhumbline Advisers owned about 0.18% of USANA Health Sciences worth $2,702,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. increased its position in shares of USANA Health Sciences by 72.6% during the second quarter. BlackRock Inc. now owns 2,302,511 shares of the company’s stock worth $182,889,000 after purchasing an additional 968,239 shares in the last quarter. Morgan Stanley boosted its holdings in USANA Health Sciences by 0.3% in the 2nd quarter. Morgan Stanley now owns 297,254 shares of the company’s stock valued at $23,611,000 after purchasing an additional 773 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in USANA Health Sciences by 13.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 271,443 shares of the company’s stock valued at $21,560,000 after purchasing an additional 31,396 shares in the last quarter. Nuveen Asset Management LLC purchased a new stake in USANA Health Sciences in the 2nd quarter valued at approximately $17,458,000. Finally, Schroder Investment Management Group boosted its holdings in USANA Health Sciences by 183.1% in the 2nd quarter. Schroder Investment Management Group now owns 212,492 shares of the company’s stock valued at $16,878,000 after purchasing an additional 137,430 shares in the last quarter. Institutional investors own 63.73% of the company’s stock.

USNA has been the topic of a number of analyst reports. ValuEngine raised USANA Health Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $86.00 price target on the stock in a research note on Saturday, October 26th. Jefferies Financial Group assumed coverage on USANA Health Sciences in a research note on Thursday, August 22nd. They set a “hold” rating and a $65.00 price target on the stock. Finally, Pivotal Research restated a “buy” rating on shares of USANA Health Sciences in a research report on Wednesday, July 24th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. USANA Health Sciences has a consensus rating of “Buy” and a consensus target price of $74.00.

In other news, Director Robert Auciaux sold 4,018 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $71.87, for a total transaction of $288,773.66. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO G Doug Iiekking sold 1,746 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $75.33, for a total transaction of $131,526.18. Following the transaction, the chief financial officer now directly owns 2,032 shares in the company, valued at approximately $153,070.56. The disclosure for this sale can be found here. Insiders have sold 8,385 shares of company stock worth $617,279 in the last ninety days. Corporate insiders own 42.50% of the company’s stock.

Shares of USNA stock traded down $0.59 on Tuesday, reaching $74.60. 1,926 shares of the stock were exchanged, compared to its average volume of 147,358. The stock has a market cap of $1.64 billion, a P/E ratio of 14.45 and a beta of 0.28. The firm has a 50 day moving average of $71.31 and a two-hundred day moving average of $71.45. USANA Health Sciences, Inc. has a 1-year low of $58.30 and a 1-year high of $125.61.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 22nd. The company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.22. The firm had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $256.22 million. USANA Health Sciences had a net margin of 9.38% and a return on equity of 27.60%. The firm’s revenue was down 12.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.24 EPS. As a group, equities analysts forecast that USANA Health Sciences, Inc. will post 3.99 EPS for the current fiscal year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Recommended Story: What does a hold rating mean?

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.